{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T17:53:41Z","timestamp":1781805221702,"version":"3.54.5"},"reference-count":45,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"unspecified","delay-in-days":25,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009010","name":"Novartis Pharmaceuticals UK Limited","doi-asserted-by":"publisher","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100009010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,1,29]]},"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>VICTORION-Spirit was a hybrid study designed to assess the feasibility of implementing inclisiran, a novel cholesterol-lowering treatment and behavioural support within primary care centres in England. This process evaluation aimed to evaluate the implementation of inclisiran for patients with elevated low-density lipoprotein cholesterol and atherosclerotic cardiovascular disease (ASCVD) or ASCVD-risk equivalents (n=900), from the perspectives of key stakeholders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>VICTORION-Spirit was a phase IIIb, multicentre, randomised, controlled study. We followed a process evaluation strategy to collate the views of stakeholders via semistructured interviews and to gain insights on the \u2018implementability\u2019 of inclisiran in primary care. Data were generated via interviews with patients, healthcare providers and research nurses and analysed using a qualitative rapid analysis approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Primary care in Greater Manchester, UK.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>84 participants were interviewed, including patients (n=56), professionals at participating practices in VICTORION-Spirit (n=13), health advisors (n=4) and research nurses (n=11).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Interim findings suggest the process of receiving and providing inclisiran during the study was \u2018straightforward\u2019, and the behavioural support provided to some patients was generally viewed favourably. Beyond the trial, patients and healthcare providers thought the delivery of inclisiran could work well as a practice nurse-provided service. Barriers to implementing inclisiran were generally related to workforce and workload pressures in primary care, and an incentive structure to support delivery was recommended.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patients and healthcare providers supported implementing inclisiran in primary care. It was convenient for patients to receive inclisiran in general practice, and most providers felt that the intervention was a useful addition to existing lipid-lowering treatments. Several barriers to implementation were highlighted, including concerns relating to general practice resources and costs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04807400\">NCT04807400<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2023-083441","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T12:52:29Z","timestamp":1740574349000},"page":"e083441","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Evaluating the implementation of inclisiran in primary care: process evaluation interim findings from interviews with key stakeholders"],"prefix":"10.1136","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct04807400","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2657-5780","authenticated-orcid":false,"given":"Paul","family":"Wilson","sequence":"first","affiliation":[{"name":"Centre for Primary Care and Health Services Research, University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3754-4979","authenticated-orcid":false,"given":"Rebecca","family":"Elvey","sequence":"additional","affiliation":[{"name":"Centre for Primary Care and Health Services Research, University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5360-3644","authenticated-orcid":false,"given":"Amy","family":"Mathieson","sequence":"additional","affiliation":[{"name":"Centre for Primary Care and Health Services Research, University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9558-3349","authenticated-orcid":false,"given":"Peter","family":"Bower","sequence":"additional","affiliation":[{"name":"Centre for Primary Care and Health Services Research, University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Gibson","sequence":"additional","affiliation":[{"name":"North West EHealth, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey","family":"Vell","sequence":"additional","affiliation":[{"name":"Health Innovation Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Dixon","sequence":"additional","affiliation":[{"name":"Implementation Science, Novartis Pharmaceuticals UK, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,2,26]]},"reference":[{"key":"2025121512155664000_15.2.e083441.1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx144"},{"key":"2025121512155664000_15.2.e083441.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31694-5"},{"key":"2025121512155664000_15.2.e083441.3","unstructured":"NHS England . Cardiovascular disease (CVD). Available: https:\/\/www.england.nhs.uk\/ourwork\/clinical-policy\/cvd\/ [Accessed 10 Feb 2023]."},{"key":"2025121512155664000_15.2.e083441.4","unstructured":"British Heart Foundation . UK factsheet. 2024. Available: https:\/\/www.bhf.org.uk\/-\/media\/files\/for-professionals\/research\/heart-statistics\/bhf-cvd-statistics-uk-factsheet.pdf?rev=3f65bfd51bdb4442b92ca5eb4fab4f77&hash=8FF3BC58031319ABF8FC258DAA4A571F [Accessed 12 Dec 2024]."},{"key":"2025121512155664000_15.2.e083441.5","unstructured":"NHS England . Summary of national guidance for lipid management for primary and secondary prevention of CVD. 2024. Available: https:\/\/www.england.nhs.uk\/aac\/publication\/summary-of-national-guidance-for-lipid-management\/ [Accessed 6 Dec 2024]."},{"key":"2025121512155664000_15.2.e083441.6","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-30060-w","article-title":"Statin therapy inhibits fatty acid synthase via dynamic protein modifications","volume":"13","author":"Trub","year":"2022","journal-title":"Nat Commun"},{"key":"2025121512155664000_15.2.e083441.7","article-title":"Statins for the primary prevention of cardiovascular disease","volume":"2013","author":"Taylor","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121512155664000_15.2.e083441.8","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000625"},{"key":"2025121512155664000_15.2.e083441.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912387"},{"key":"2025121512155664000_15.2.e083441.10","unstructured":"Novartis Pharmaceuticals . Leqvio (inclisiran) summary of product characteristics. Available: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/leqvio-epar-product-information_en.pdf [Accessed 10 Feb 2023]."},{"key":"2025121512155664000_15.2.e083441.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1913805"},{"key":"2025121512155664000_15.2.e083441.12","first-page":"S19","article-title":"Inclisiran: testing a population health management methodology to implement a novel lipid treatment","volume":"28","author":"Dixon","year":"2021","journal-title":"Br J Cardiol"},{"key":"2025121512155664000_15.2.e083441.13","doi-asserted-by":"crossref","DOI":"10.1186\/s13012-022-01245-0","article-title":"The updated Consolidated Framework for Implementation Research based on user feedback","volume":"17","author":"Damschroder","year":"2022","journal-title":"Implement Sci"},{"key":"2025121512155664000_15.2.e083441.14","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.h1258","article-title":"Process evaluation of complex interventions: Medical Research Council guidance","volume":"350","author":"Moore","year":"2015","journal-title":"BMJ"},{"key":"2025121512155664000_15.2.e083441.15","doi-asserted-by":"crossref","first-page":"156","DOI":"10.18203\/2349-3259.ijct20231106","article-title":"Implementation of inclisiran in United Kingdom primary care for patients with atherosclerotic cardiovascular disease or its-risk equivalents: rationale and design of Victorion-spirit, a pragmatic phase IIIb, randomised controlled study","volume":"10","author":"Wilson","year":"2023","journal-title":"Int J Clin Trials"},{"key":"2025121512155664000_15.2.e083441.16","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12195"},{"key":"2025121512155664000_15.2.e083441.17","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.sbspro.2010.07.328","article-title":"The effectiveness of motivational interviewing in improving health outcomes in adults with type 2 diabetes","volume":"5","author":"Pourisharif","year":"2010","journal-title":"Procedia Soc Behav Sci"},{"key":"2025121512155664000_15.2.e083441.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijnurstu.2011.11.011"},{"key":"2025121512155664000_15.2.e083441.19","doi-asserted-by":"publisher","DOI":"10.1177\/2047487315569401"},{"key":"2025121512155664000_15.2.e083441.20","doi-asserted-by":"publisher","DOI":"10.1186\/1748-5908-4-50"},{"key":"2025121512155664000_15.2.e083441.21","doi-asserted-by":"crossref","DOI":"10.1186\/s13012-016-0437-z","article-title":"A systematic review of the use of the Consolidated Framework for Implementation Research","volume":"11","author":"Kirk","year":"2016","journal-title":"Implement Sci"},{"key":"2025121512155664000_15.2.e083441.22","doi-asserted-by":"crossref","DOI":"10.1186\/s13012-019-0853-y","article-title":"Comparison of rapid vs in-depth qualitative analytic methods from a process evaluation of academic detailing in the Veterans Health Administration","volume":"14","author":"Gale","year":"2019","journal-title":"Implement Sci"},{"key":"2025121512155664000_15.2.e083441.23","unstructured":"Hamilton AB . Qualitative methods in rapid turn-around health services research. 2013. Available: https:\/\/www.hsrd.research.va.gov\/for_researchers\/cyber_seminars\/archives\/780-notes.pdf [Accessed 11 Dec 2024]."},{"key":"2025121512155664000_15.2.e083441.24","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-13-117","article-title":"Using the framework method for the analysis of qualitative data in multi-disciplinary health research","volume":"13","author":"Gale","year":"2013","journal-title":"BMC Med Res Methodol"},{"key":"2025121512155664000_15.2.e083441.25","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-076792","article-title":"Development and application of a qualitative rapid analysis framework in a hybrid trial within primary care","volume":"14","author":"Mathieson","year":"2024","journal-title":"BMJ Open"},{"key":"2025121512155664000_15.2.e083441.26","doi-asserted-by":"crossref","DOI":"10.5688\/ajpe7120","article-title":"A Review of the Quality Indicators of Rigor in Qualitative Research","volume":"84","author":"Johnson","year":"2020","journal-title":"Am J Pharm Educ"},{"key":"2025121512155664000_15.2.e083441.27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615758"},{"key":"2025121512155664000_15.2.e083441.28","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S2213-8587(22)00353-9","article-title":"Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial","volume":"11","author":"Ray","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025121512155664000_15.2.e083441.29","unstructured":"National Institute for Health and Care Excellence (NICE) . Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia. Technology appraisal guidance [TA733]. 2021. Available: https:\/\/www.nice.org.uk\/guidance\/ta733 [Accessed 10 Feb 2023]."},{"key":"2025121512155664000_15.2.e083441.30","unstructured":"Royal College of General Practitioners . RCGP and BMA update: information on the proposals for the prescription of inclisiran in primary care settings. 2022. Available: https:\/\/www.rcgp.org.uk\/representing-you\/policy-areas\/inclisiran-position-statement#:~:text=Inclisiran%20is%20a%20new%20and,of%20PCSK9%20in%20the%20liver [Accessed 10 Feb 2023]."},{"key":"2025121512155664000_15.2.e083441.31","unstructured":"Health Economics Research Group, Office of Health Economics, RAND Europe . Medical research: what\u2019s it worth? estimating the economic benefits from medical research in the UK. 2008. Available: https:\/\/www.ukri.org\/wp-content\/uploads\/2022\/02\/MRC-030222-medical-research-whats-it-worth.pdf [Accessed 10 Feb 2023]."},{"key":"2025121512155664000_15.2.e083441.32","doi-asserted-by":"crossref","first-page":"A67","DOI":"10.1136\/heartjnl-2017-311726.91","article-title":"92\u2005Primary care prescriptions for statins in england 1998\u20132015","volume":"103","author":"Raza","year":"2017","journal-title":"Heart"},{"key":"2025121512155664000_15.2.e083441.33","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4103\/1995-705X.95070","article-title":"Statins: past and present","volume":"12","author":"Hajar","year":"2011","journal-title":"Heart Views"},{"key":"2025121512155664000_15.2.e083441.34","doi-asserted-by":"crossref","first-page":"23","DOI":"10.14797\/mdcj-15-1-23","article-title":"Statins: Then and Now","volume":"15","author":"Toth","year":"2019","journal-title":"Methodist Debakey Cardiovasc J"},{"key":"2025121512155664000_15.2.e083441.35","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e3182408812"},{"key":"2025121512155664000_15.2.e083441.36","doi-asserted-by":"crossref","DOI":"10.1186\/1748-5908-8-S1-S2","article-title":"Effectiveness-implementation hybrid designs: implications for quality improvement science","volume":"8","author":"Bernet","year":"2013","journal-title":"Implementation Sci"},{"key":"2025121512155664000_15.2.e083441.37","doi-asserted-by":"crossref","first-page":"104155","DOI":"10.1016\/j.ijnurstu.2021.104155","article-title":"The impact of COVID-19 on the wellbeing of the UK nursing and midwifery workforce during the first pandemic wave: A longitudinal survey study","volume":"127","author":"Couper","year":"2022","journal-title":"Int J Nurs Stud"},{"key":"2025121512155664000_15.2.e083441.38","doi-asserted-by":"publisher","DOI":"10.3399\/BJGP.2021.0680"},{"key":"2025121512155664000_15.2.e083441.39","unstructured":"British Medical Association . Pressures in general practice data analysis. 2023. Available: https:\/\/www.bma.org.uk\/advice-and-support\/nhs-delivery-and-workforce\/pressures\/pressures-in-general-practice-data-analysis [Accessed 10 Feb 2023]."},{"key":"2025121512155664000_15.2.e083441.40","unstructured":"Kirby D . Manchester named as heart disease capital of England. 2014. Available: https:\/\/www.manchestereveningnews.co.uk\/news\/health\/manchester-englands-heart-disease-capital-7571811 [Accessed 10 Feb 2023]."},{"key":"2025121512155664000_15.2.e083441.41","unstructured":"Office of National Statistics . Census table KS102EW age structure. 2011. Available: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/populationandmigration\/populationestimates\/datasets\/2011censuskeystatisticsforlocalauthoritiesinenglandandwales [Accessed 10 Feb 2023]."},{"key":"2025121512155664000_15.2.e083441.42","unstructured":"Office of National Statistics . Census table KS201EW ethnic group. 2011. Available: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/populationandmigration\/populationestimates\/datasets\/2011censuskeystatisticsforlocalauthoritiesinenglandandwales [Accessed 10 Feb 2023]."},{"key":"2025121512155664000_15.2.e083441.43","unstructured":"Quality Outcomes Framework . Key indicators of representativeness of the greater manchester population to the UK. 2022. Available: https:\/\/www.gpcontract.co.uk\/browse\/14L\/22 [Accessed 10 Feb 2023]."},{"key":"2025121512155664000_15.2.e083441.44","doi-asserted-by":"crossref","DOI":"10.1186\/s12890-015-0150-8","article-title":"The Salford Lung Study protocol: a pragmatic, randomised phase III real-world effectiveness trial in asthma","volume":"15","author":"Woodcock","year":"2015","journal-title":"BMC Pulm Med"},{"key":"2025121512155664000_15.2.e083441.45","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1093\/cvr\/cvae109","article-title":"Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial","volume":"120","author":"Wright","year":"2024","journal-title":"Cardiovasc Res"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2023-083441","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T20:16:08Z","timestamp":1765829768000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2023-083441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":45,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2,26]]},"published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1136\/bmjopen-2023-083441"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2023-083441","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2]]}}}